Preventing Failure Before First Patient In

Why Protocol Design Determines the Success of Early-Stage Clinical Trials

Executive Summary

A significant proportion of early-stage clinical trials fail because the trial was incorrectly designed. Across academia, biotech and pharmaceuticals, as well as investigator-initiated studies, protocol design is a crucial pillar of the study and cannot be treated as an administrative prerequisite. Otherwise, studies suffer from predictable and preventable issues including:

• Uninterpretable endpoints

• Underpowered sample size

• Inappropriate inclusion criteria

• Operationally difficult visit schedules

• Regulatory rejection

• Recruitment collapse

• Post-hoc statistical salvage attempts

By the time these problems become visible, the study has already consumed funding, time, and credibility. Maxeome exists to intervene at the protocol architecture stage, where the majority of trial failure risk originates.

This paper explains:

1. Why early clinical studies systematically fail

2. Where current CRO and academic workflows break down

3. How protocol design dramatically increases trial viability

4. The Maxeome methodological framework

The Underestimated Cause of Clinical Trial Failure

Discussions around clinical trials often focus on drugs failing in their efficacy, when in reality, many studies never tested the efficacy properly. A trial is a measurement instrument, when flawed, the output is meaningless regardless of the drug's efficacy.

The Measurement Problem

Most CROs execute trials, but they are not incentivized to challenge the scientific premise.

Their incentives:

• Implement sponsor decisions

• Minimize amendments

• Preserve timeline

They optimize execution efficiency, not question validity.

Most early studies unintentionally test a mixture of variables:

Intended Question	What Actually Gets Tested
Does the therapy work?	Does it work in this specific logistical scenario?
Is the biomarker predictive?	Is the biomarker detectable under noisy or imperfect conditions?
Is there clinical improvement?	Is improvement detectable within an unspecified timeframe?

Existing Workflows Produce Weak Protocols

Academic Investigators

Researchers are domain experts in their field, not experimental architects under regulatory and operational constraints.

The typically observed sequence: (1) Hypothesis formed. (2) Endpoint chosen based on literature. (3) Sample size estimated. (4) Study submitted.

What is missing:

• Operational feasibility modeling

• Signal detectability analysis

• Visit burden modeling

• Behavioral compliance modeling

• Statistical sensitivity

And a whole lot more of operational details that Investigators do not have the capacity to handle.

Biotech Startups

Biotech companies operate under capital pressure alongside scientific pressure.

Their first clinical study is rarely designed purely to answer a scientific question. It is designed to unlock the next financing event. Consequently, they face the fundraising trial problem.

Early biotech trials frequently attempt to accomplish multiple incompatible goals:

• Demonstrate safety

• Show efficacy signal

• Identify responders

• Validate biomarker

• Support valuation narrative

• Impress investors

Result	Investor Interpretation	Scientific Meaning
Small positive subgroup	Promising	Underpowered noise
Trend toward efficacy	Encouraging	Non-interpretable
Mixed endpoints	Complex biology	Poor design

Startups frequently over-engineer inclusion criteria to maximize apparent signal:

• Narrow biomarker windows

• Restrictive comorbidity exclusions

• Artificially controlled populations

This undermines external validity and future scalability which causes the Phase II trial to fails, not because the therapy stopped working, but because the original study tested a non-realistic population.

Pharmaceutical Sponsors

Large pharmaceutical companies face the opposite problem of startups: process saturation. They possess internal expertise, established standard operating procedures (SOPs), and regulatory experience. However, scale introduces its own structural challenges.

Large organizations rely on historical protocol templates derived from previous programs.

This creates hidden assumptions:

• Standard visit schedules

• Conventional endpoints

• Traditional inclusion logic

• Default statistical frameworks

The trial becomes familiar rather than groundbreaking.

In large sponsors, protocol construction is distributed:

Group	Priority
Clinical	Feasibility
Regulatory	Acceptability
Statistics	Power
Medical	Mechanism
Operations	Logistics

Experience reduces obvious errors but does not prevent structural ones. Many late-stage trial failures originate from inherited design logic applied to novel mechanisms. The organization knows how to run trials, but it does not always know whether the trial is the correct experiment.

The Maxeome Framework

Phase 1: Question Validation

We reconstruct the actual scientific question being asked. Many protocols unintentionally ask a different question than intended due to endpoint structure.

We do this by:

• Question alignment analysis

• Endpoint validity assessment

• Signal pathway mapping

  
  

Phase 2: Detectability Modeling

We determine whether the study can realistically detect the effect it seeks as this often changes measurement strategy entirely, including:

• Variance analysis

• Effect size realism

• Power sensitivity modeling

• Time-window detectability

Phase 3: Operational Stress Testing

We simulate real-world execution constraints.

We model:

• Recruitment behavior

• Dropout probability

• Visit compliance

• Site burden

• Measurement noise

Phase 4: Interpretability Protection

We design the protocol so every outcome has meaning. Every possible result should map to a scientific conclusion.

Case Patterns Observed Across Studies

Across early-stage trials, recurring design errors appear:

Pattern A: Endpoint Drift

The endpoint reflects what is easy to measure, not what proves efficacy.

Pattern B: Over-Narrow Inclusion

Researchers restrict populations to increase signal, unintentionally destroying recruitment and generalizability.

Pattern C: Visit Overload

High visit frequency causes behavioral noncompliance, increasing variance and masking effects.

Pattern D: Statistical Illusion

Power calculations assume ideal conditions that never occur in human studies.

Impact of Early Intervention

Protocol correction at design stage prevents:

• Failed pilot studies

• Expensive amendments

• Ethics committee rejection

• Null Phase II transitions

• Investor skepticism

• Scientific reputational damage

The cost of correcting a protocol before IRB submission is negligible compared to correcting conclusions after completion.

Who Benefits?

Maxeome primarily supports:

• Biotech startups planning first-in-human or pilot studies

• Academic investigators conducting investigator-initiated trials

• Research groups transitioning from preclinical to clinical

• Companies preparing regulatory-grade evidence